REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome

Clinical trial NCT06914609 · RECRUITING

Trial details

NCT number: NCT06914609
Sponsor: Ionis Pharmaceuticals, Inc.
Status: RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

Angelman Syndrome

Start date: 2025-06-10
Primary completion: 2027-08-01
Enrollment: 158

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.